Quốc gia: Úc
Ngôn ngữ: Tiếng Anh
Nguồn: APVMA (Australian Pesticides and Veterinary Medicines Authority)
BORDETELLA BRONCHISEPTICA; CANINE PARAINFLUENZA VIRUS
INTERVET AUSTRALIA PTY LIMITED
vaccine - canine Bordetella+vaccine - canine parainfluen
MISC. VACCINES OR ANTI SERA
BORDETELLA BRONCHISEPTICA VACCINE-MICROBIAL Active 0.0 Undefined; CANINE PARAINFLUENZA VIRUS VACCINE-VIRAL Active 0.0 Undefined
10x1 vials; 20 x 1dose; 25 x 1dose; 50 x 1dose; 5x1 vials
VM - Veterinary Medicine
INTERVET AUSTRALIA
DOG - OVER 4 WEEKS OLD | PUPPY
IMMUNOTHERAPY
KENNEL COUGH | INFECTIOUS TRACHEOBRONCHITIS
Poison schedule: 4; Withholding period: WHP: N/A; Host/pest details: DOG - OVER 4 WEEKS OLD: [KENNEL COUGH]; Live intranasal vaccine to aid in protection against kennel cough disease caused by Bordetella bronchiseptica & canine parainfluenza virus for at least 12 months following vaccination.Dogs should be at least 4 weeks of age. Only healthy dogs should be vaccinated.
Registered
2023-07-01
For Official Use Only E-LABEL APPLICATION (DRAFT) COMPANY NAME: INTERVET AUSTRALIA PTY LIMITED PRODUCT NAME: NOBIVAC KC CONTINUUM VACCINE ELABEL APPLICATION NO: DC12-33310838E3 APVMA APPROVAL NO: 59010/100769 PRODUCT NO: 59010 VERSION NO: 4.0 APPLICATION STARTED: 2014-Oct-23 13:41:29 VERSION CREATED: 2015-Feb-13 11:44:06 STARTED BY: Lyn Lavidis PRINTED: 2015-Feb-13 15:27:01 LABEL NAME: NOBIVAC KC CONTINUUM VACCINE SIGNAL HEADINGS: PRESCRIPTION ANIMAL REMEDY KEEP OUT OF REACH OF CHILDREN FOR ANIMAL TREATMENT ONLY CONSTITUENT STATEMENTS: Contains avirulent live Bordetella bronchiseptica and canine parainfluenza virus. Contains per dose: 10^8.0 CFU Bordetella bronchiseptica 10^4.0 TCID50 Canine parainfluenza virus ACTIVE CONSTITUENTS: Each single dose contains at least: 10^8.0 cfu Bordetella bronchiseptica (living, B-C2 strain) and 10^4.0 TCID50 canine parainfluenza virus (living, Cornell strain). CLAIMS: Live intranasal vaccine to aid in protection against Kennel Cough disease caused by Bordetella bronchiseptica and canine parainfluenza virus for at least 12 months following vaccination. NET CONTENTS: 10 x single dose vials 20 x single dose vials 25 x single dose vials 50 x single dose vials 5 x single dose vials Single dose vial. DIRECTIONS FOR USE: DIRECTIONS FOR USE: PRECAUTIONS: PRECAUTIONS This product should not be used on dogs less than 4 weeks of age. This product should be administered at least 72 hours prior to the anticipated risk of exposure (e.g. kennelling). RLP APPROVED For Official Use Only This product should only be administered to healthy dogs. Nobivac® KC contains live attenuated B. bronchiseptica, dogs on antibacterial therapy with activity against B. bronchiseptica are unlikely to respond to vaccination. SIDE EFFECTS: SIDE EFFECTS Occasionally, particularly in very young susceptible puppies, signs of upper respiratory tract disease may sometimes be seen, including mild discharges from the eyes and nose, sneezing and coughing. Signs are generally transient, but in occasional cases may persist Đọc toàn bộ tài liệu
PRODUCT NAME: NOBIVAC® KC CONTINUUM VACCINE MATERIAL SAFETY DATA SHEET THIS REVISION ISSUED: JULY, 2009 PAGE: 1 OF 5 MATERIAL SAFETY DATA SHEET Issued by: Intervet Australia Pty Limited Phone: 1 800 033 461 (Business Hours) Poisons Information Centre: 13 11 26 from anywhere in Australia, (0800 764 766 in New Zealand) SUBSTANCE: Freeze dried mix of bacteria and virus, together with buffering and other ingredients necessary for successful reconstitution. TRADE NAME: NOBIVAC ® KC CONTINUUM VACCINE RECOMMENDED USE: For the protection of dogs against Kennel Cough disease caused by _Bordetella _ _bronchiseptica_, and canine parainfluenza virus. APVMA NO: 59010 CREATION DATE: July, 2006 THIS VERSION ISSUED: July, 2009 and is valid for 5 years from this date. NOTE: These products are sold in two parts; a freeze dried solid and a sterile diluent. As the diluent is essentially water, offering no reasonably anticipated possibility of hazard, this MSDS concentrates on the freeze dried solid component. STATEMENT OF HAZARDOUS NATURE: THIS PRODUCT IS CLASSIFIED AS: Not classified as hazardous according to the criteria of SWA. Not a Dangerous Good according to the Australian Dangerous Goods (ADG) Code. RISK PHRASES: Not Hazardous - No criteria found. SAFETY PHRASES: S22, S25. Do not breathe dust. Avoid contact with eyes. SUSDP CLASSIFICATION: S4 ADG CLASSIFICATION: None allocated. Not a Dangerous Good under the ADG Code. UN NUMBER: None allocated PHYSICAL DESCRIPTION & COLOUR: Milky white solid. ODOUR: No data. MAJOR HEALTH HAZARDS: no significant risk factors have been found for this product. PATHOGENICITY: THE ORGANISMS IN THIS PRODUCT ARE NOT PATHOGENIC FOR HUMANS._._ INHALATION: SHORT TERM EXPOSURE: Available data indicates that this product is not harmful. However product may be mildly irritating, although unlikely to cause anything more than mild transient discomfort. LONG TERM EXPOSURE: No data for health effects associated with long term inhalation. SKIN CONTACT: SHORT TERM EXPOSURE: Available data indicates that this Đọc toàn bộ tài liệu